A new Ro survey shows GLP-1 stigma falls when people know someone taking the medication, suggesting personal ties are driving acceptance.
Popular drugs like Ozempic are now a part of official global health recommendations from the World Health Organization to treat obesity.
While Americans see the benefits of GLP-1s, skepticism about relying on an injection to lose weight still runs deep, a new survey finds.
Search trends and survey data show where interest in weight loss drugs like Ozempic and Wegovy is surging in America.
A new survey from AlynMD reveals shifting attitudes toward weight loss medications like Ozempic and which generation is most on board.
WeightWatchers partners with U.K.-based CheqUp to expand GLP-1 support, following news of its Chapter 11 and focus on long-term growth.
Zepbound helped patients lose more weight than Wegovy in a 72-week trial, with greater reductions in both body weight and waist size.
WeightWatchers has filed for Chapter 11 bankruptcy as part of a financial restructuring and a renewed focus on telehealth.
New data shows U.S. consumer spending on GLP-1 drugs like Ozempic, Wegovy and Mounjaro soared from $13.7B to $71.7B between 2018 and 2023.
Weight-reducing drugs such as Ozempic and Wegovy are changing how Americans eat, paving the way for nutrition brands to make their mark.
Sign Up to Our Newsletter
